Peer-Reviewed Publications

      BEL networks derived from qualitative translations of BioNLP shared task annotations

      Fluck, J.; Klenner, A.; Madan, S.; Ansari, S.; Bobic, T.; Hoeng, J.; Hofman-Apitius, M.; Peitsch, M. C.
      Published
      Aug 8, 2013
      Link to publication
      Topic
      Summary

      Interpreting the rapidly increasing amount of experimental data requires the availability and representation of biological knowledge in a computable form. The Biological expression language (BEL) encodes the data in form of causal relationships, which describe the association between biological events. BEL can successfully be applied to large data and support causal reasoning and hypothesis generation. With the rapid growth of biomedical literature, automated methods are a crucial prerequisite for handling and encoding the available knowledge. The BioNLP shared tasks support the development of such tools and provide a linguistically motivated format for the annotation of relations. On the other hand, BEL statements and the corresponding evidence sentences might be a valuable resource for future BioNLP shared task training data generation. In this paper, we briefly introduce BEL and investigate how far BioNLP-shared task annotations could be converted to BEL statements and in such a way directly support BEL statement generation. We present the first results of the automatic BEL statement generation and emphasize the need for more training data that captures the underlying biological meaning.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.